Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus carotuximab versus axitinib alone in previously treated advanced or metastatic renal cell carcinoma
2015-003436-13Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Apr 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) comparing Axitinib + carotuximab with Axitinib alone (2 arms). Primary endpoint: Progression-free survival. Started Apr 2016; status: completed.
02
Drugs
axitinibcarotuximab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2015-003436-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003436-13.